Characterization and management of adverse reactions from the CLEAR study in advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab-Reference-Cited by-同舟云学术

Characterization and management of adverse reactions from the CLEAR study in advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab

Published:2023-08-11 Issue:2 Volume:19 Page:29-40
ISSN:1996-1812
Container-title:Cancer Urology
language:
Short-container-title:Onkourologiâ

Author:

Motzer R.¹,George S.²,Merchan J. R.³,Hutson T. E.⁴,Song X.⁵,Perini R. F.⁵,Xie R.⁶,Bapat U.⁷,Puente J.⁸

Affiliation:

1. Memorial Sloan Kettering Cancer Center

2. Roswell Park Comprehensive Cancer Center

3. University of Miami Sylvester Comprehensive Cancer Center

4. Texas Oncology-Baylor Charles A. Sammons Cancer Center

5. Clinical Research, Merck & Co., Inc.

6. Biostatistics, Eisai Inc.

7. Clinical Research, Eisai Inc.

8. Hospital Clinico Universitario San Carlos

Abstract

Publisher

Publishing House ABV Press

Subject

Urology,Nephrology,Radiology, Nuclear Medicine and imaging,Oncology,Surgery

Reference22 articles.

1. Motzer R., Alekseev B., Rha S.Y. et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 2021;384(14):1289–300. DOI: 10.1056/NEJMoa2035716

2. Lenvima® (lenvatinib) [prescribing information]. Nutley, NJ, USA: Eisai Inc., 2021.

3. Kisplyx 4 mg and 10 mg hard capsules [summary of product characteristics]. Frankfurt am Main, Germany: Eisai GmbH, 2021.

4. Keytruda® (pembrolizumab) [prescribing information]. Whitehouse Station, NJ, USA: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., 2022.

5. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for industry: adverse reactions section of labeling for human prescription drug and biological products – content and format 2006. Accessed June 1, 2022. Available at: https://www.fda.gov/media/72139/download.